Roche pulls dan­gling ac­cel­er­at­ed ap­proval for Tecen­triq in triple-neg­a­tive breast can­cer

Roche on Fri­day de­cid­ed to vol­un­tar­i­ly pull an in­di­ca­tion won via the FDA’s ac­cel­er­at­ed ap­proval path­way for its block­buster PD-L1 drug Tecen­triq.

This is the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER